Back to Search

SULEIMAN MASSARWEH, MD

MD

Medical Oncology Physician

NPI: 1972619708Individual

Specialties, Licenses & Credentials

Medical Oncology PhysicianPrimary

Internal Medicine — Medical Oncology

Code: 207RX0202X

C133507(CA)
Hematology & Oncology Physician

Internal Medicine — Hematology & Oncology

Code: 207RH0003X

40219(KY)

Research & Publications (16)

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
PMID 18245484·Cancer Res·2008
7-preclinical
Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.
PMID 17404074·Clin Cancer Res·2007
6-review
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
PMID 16912207·Cancer Res·2006
7-preclinical
Unusual sites of malignancy: case 3. Solitary splenic metastasis in lung cancer with spontaneous rupture.
PMID 11230502·J Clin Oncol·2001
5-case
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
PMID 18794137·Cancer Res·2008
7-preclinical
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
PMID 17470737·J Natl Cancer Inst·2007
7-preclinical
Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
PMID 17259554·Endocr Relat Cancer·2006
6-review
Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan.
PMID 16799708·Pathol Oncol Res·2006
8-other
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
PMID 16273359·Cancer Chemother Pharmacol·2005
6-review
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
PMID 15701879·Clin Cancer Res·2005
6-review
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
PMID 15199112·J Natl Cancer Inst·2004
7-preclinical
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance.
PMID 14734488·Clin Cancer Res·2004
7-preclinical
Small-cell cancers, and an unusual reaction to chemotherapy. Case 2. Synchronous renal cell carcinoma and limited-stage small-cell lung cancer.
PMID 12805345·J Clin Oncol·2003
5-case
HIV-related Hodgkin's disease with central nervous system involvement and association with Epstein-Barr virus.
PMID 12605396·Am J Hematol·2003
5-case
Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
PMID 12538499·Clin Cancer Res·2003
6-review
Erythroblast island.
PMID 11940497·Haematologica·2002
8-other

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
300 PASTEUR DR
STANFORD, CA 94305

Location

Practice Location

300 PASTEUR DR, STANFORD, CA
(650) 723-4000

Quick Facts

NPI
1972619708
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
2
Locations
1
Publications
16

Are you this provider?

Claim Your Profile